In its home health and DMEPOS final rule released in December 2025, effective Jan. 1, 2026, CMS is now requiring DMEPOS suppliers to be surveyed and reaccredited every year (as opposed to the current 3-year cycle). In September 2025, NCPA submitted comments to CMS on its proposed rule. In our comments, NCPA opposed the annual survey and reaccreditation requirement due to the increased administrative burden and costs expected for pharmacies, among other reasons.
CMS had also stated that it finalized its proposal to make payment under the DMEPOS competitive bidding program (CBP) for certain continuous glucose monitors (CGMs) and insulin infusion pumps, and all necessary supplies and accessories, on a bundled monthly rental basis. CMS also finalized its proposal that payment for CGMs, insulin infusion pumps, and all necessary supplies and accessories that are not furnished under the DMEPOS CBP be made on a bundled monthly rental basis, with payments limited to the amounts established for CGMs and insulin infusion pumps under the DMEPOS CBP.
In our comments in September, NCPA opposed CMS' proposal to reclassify all CGMs and insulin infusion pumps under the DMEPOS CBP. NCPA also urged CMS to expand access to needed diabetes services by covering CGMs delivered by pharmacists and other qualified practitioners under direct or general (preferable) supervision.
Additionally, NCPA and other stakeholder groups including the National Association of Boards of Pharmacy, National Association of Chain Drug Stores, Walgreens, Walmart, and CVS Health voiced their concerns about the rule in a call with CMS on Nov. 19.
NCPA advises members to please work with their accreditation entities on compliance with this new final rule. NCPA will keep our members posted on further developments.
